Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 348

1.
2.

Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis.

Bucsics T, Grasl B, Ferlitsch A, Schwabl P, Mandorfer M, Zinober K, Stern R, Chromy D, Scheiner B, Sieghart W, Peck-Radosavljevic M, Trauner M, Reiberger T.

Ultrasound Med Biol. 2018 Dec;44(12):2578-2586. doi: 10.1016/j.ultrasmedbio.2018.07.031. Epub 2018 Sep 18.

PMID:
30241728
3.

Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?

Pinter M, Sieghart W.

Memo. 2018;11(3):185-192. doi: 10.1007/s12254-018-0431-z. Epub 2018 Aug 24. Review.

4.

The α6 subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation.

Fan PC, Lai TH, Hor CC, Lee MT, Huang P, Sieghart W, Ernst M, Knutson DE, Cook J, Chiou LC.

Neuropharmacology. 2018 Sep 15;140:1-13. doi: 10.1016/j.neuropharm.2018.07.017. Epub 2018 Jul 21.

PMID:
30016665
5.

Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma.

Haider C, Hnat J, Wagner R, Huber H, Timelthaler G, Grubinger M, Coulouarn C, Schreiner W, Schlangen K, Sieghart W, Peck-Radosavljevic M, Mikulits W.

Hepatology. 2018 Jul 16. doi: 10.1002/hep.30166. [Epub ahead of print]

PMID:
30014484
6.

Engineered Flumazenil Recognition Site Provides Mechanistic Insight Governing Benzodiazepine Modulation in GABAA Receptors.

Siebert DCB, Bampali K, Puthenkalam R, Varagic Z, Sarto-Jackson I, Scholze P, Sieghart W, Mihovilovic MD, Schnürch M, Ernst M.

ACS Chem Biol. 2018 Aug 17;13(8):2040-2047. doi: 10.1021/acschembio.8b00145. Epub 2018 Jul 23.

PMID:
29989390
7.

Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABAA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys.

Duke AN, Meng Z, Platt DM, Atack JR, Dawson GR, Reynolds DS, Tiruveedhula VVNPB, Li G, Stephen MR, Sieghart W, Cook JM, Rowlett JK.

J Pharmacol Exp Ther. 2018 Jul;366(1):145-157. doi: 10.1124/jpet.118.249250. Epub 2018 May 2.

PMID:
29720564
8.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.

PMID:
29625879
9.

Cerebellar α6 -subunit-containing GABAA receptors: a novel therapeutic target for disrupted prepulse inhibition in neuropsychiatric disorders.

Chiou LC, Lee HJ, Ernst M, Huang WJ, Chou JF, Chen HL, Mouri A, Chen LC, Treven M, Mamiya T, Fan PC, Knutson DE, Witzigmann C, Cook J, Sieghart W, Nabeshima T.

Br J Pharmacol. 2018 Jun;175(12):2414-2427. doi: 10.1111/bph.14198. Epub 2018 May 10.

PMID:
29518821
10.

Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability.

Knutson DE, Kodali R, Divović B, Treven M, Stephen MR, Zahn NM, Dobričić V, Huber AT, Meirelles MA, Verma RS, Wimmer L, Witzigmann C, Arnold LA, Chiou LC, Ernst M, Mihovilovic MD, Savić MM, Sieghart W, Cook JM.

J Med Chem. 2018 Mar 22;61(6):2422-2446. doi: 10.1021/acs.jmedchem.7b01664. Epub 2018 Mar 6.

PMID:
29481759
11.

Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience.

Bucsics T, Schoder M, Diermayr M, Feldner-Busztin M, Goeschl N, Bauer D, Schwabl P, Mandorfer M, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T.

PLoS One. 2018 Jan 9;13(1):e0189414. doi: 10.1371/journal.pone.0189414. eCollection 2018.

12.

Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W.

United European Gastroenterol J. 2017 Nov;5(7):987-996. doi: 10.1177/2050640617695698. Epub 2017 Feb 26.

13.

GABAA receptor subunits in the human amygdala and hippocampus: Immunohistochemical distribution of 7 subunits.

Stefanits H, Milenkovic I, Mahr N, Pataraia E, Hainfellner JA, Kovacs GG, Sieghart W, Yilmazer-Hanke D, Czech T.

J Comp Neurol. 2018 Feb 1;526(2):324-348. doi: 10.1002/cne.24337. Epub 2017 Oct 29.

PMID:
29023704
14.

Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib.

Rohr-Udilova N, Klinglmüller F, Seif M, Hayden H, Bilban M, Pinter M, Stolze K, Sieghart W, Peck-Radosavljevic M, Trauner M.

Oncotarget. 2017 Jul 6;8(34):57109-57120. doi: 10.18632/oncotarget.19055. eCollection 2017 Aug 22.

15.

Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice.

Bucsics T, Schoder M, Goeschl N, Schwabl P, Mandorfer M, Diermayr M, Feldner M, Riedl F, Bauer D, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T.

Dig Liver Dis. 2017 Dec;49(12):1360-1367. doi: 10.1016/j.dld.2017.08.002. Epub 2017 Aug 8.

PMID:
28869158
16.

The impact of thyroid hormones on patients with hepatocellular carcinoma.

Pinter M, Haupt L, Hucke F, Bota S, Bucsics T, Trauner M, Peck-Radosavljevic M, Sieghart W.

PLoS One. 2017 Aug 3;12(8):e0181878. doi: 10.1371/journal.pone.0181878. eCollection 2017.

17.

Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model.

Hubmann R, Sieghart W, Schnabl S, Araghi M, Hilgarth M, Reiter M, Demirtas D, Valent P, Zielinski C, Jäger U, Shehata M.

Front Pharmacol. 2017 Jul 7;8:319. doi: 10.3389/fphar.2017.00319. eCollection 2017.

18.

Early response evaluation using CT-perfusion one day after transarterial chemoembolization for HCC predicts treatment response and long-term disease control.

Tamandl D, Waneck F, Sieghart W, Unterhumer S, Kölblinger C, Baltzer P, Ba-Ssalamah A, Loewe C.

Eur J Radiol. 2017 May;90:73-80. doi: 10.1016/j.ejrad.2017.02.032. Epub 2017 Feb 22.

PMID:
28583650
19.

Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.

Scheiner B, Parada-Rodriguez D, Bucsics T, Schwabl P, Mandorfer M, Pfisterer N, Riedl F, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T.

Scand J Gastroenterol. 2017 Sep;52(9):1008-1015. doi: 10.1080/00365521.2017.1329456. Epub 2017 May 22.

PMID:
28532189
20.

Cancer and liver cirrhosis: implications on prognosis and management.

Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W.

ESMO Open. 2016 Mar 17;1(2):e000042. eCollection 2016. Review.

21.

Personalized treatment of patients with very early hepatocellular carcinoma.

Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, Van Poucke S, Pawlik TM.

J Hepatol. 2017 Feb;66(2):412-423. doi: 10.1016/j.jhep.2016.09.012. Epub 2016 Sep 24. Review.

PMID:
27677712
22.

First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development.

Jonas O, Calligaris D, Methuku KR, Poe MM, Francois JP, Tranghese F, Changelian A, Sieghart W, Ernst M, Krummel DA, Cook JM, Pomeroy SL, Cima M, Agar NY, Langer R, Sengupta S.

J Biomed Nanotechnol. 2016 Jun;12(6):1297-302.

23.

Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.

Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer AF, Reiberger T, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-Radosavljevic M.

J Hepatol. 2016 Oct;65(4):692-699. doi: 10.1016/j.jhep.2016.05.027. Epub 2016 May 27.

PMID:
27242316
24.

The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites.

Bucsics T, Schwabl P, Mandorfer M, Bota S, Sieghart W, Ferlitsch A, Trauner M, Reiberger T, Peck-Radosavljevic M.

Liver Int. 2016 Nov;36(11):1649-1656. doi: 10.1111/liv.13160. Epub 2016 Jun 30.

PMID:
27169985
25.

Formation of GABAA receptor complexes containing α1 and α5 subunits is paralleling a multiple T-maze learning task in mice.

Ghafari M, Falsafi SK, Szodorai E, Kim EJ, Li L, Höger H, Berger J, Fuchs K, Sieghart W, Lubec G.

Brain Struct Funct. 2017 Jan;222(1):549-561. doi: 10.1007/s00429-016-1233-x. Epub 2016 May 7.

PMID:
27155990
26.

Mutagenesis and computational docking studies support the existence of a histamine binding site at the extracellular β3+β3- interface of homooligomeric β3 GABAA receptors.

Hoerbelt P, Ramerstorfer J, Ernst M, Sieghart W, Thomson JL, Hough LB, Fleck MW.

Neuropharmacology. 2016 Sep;108:252-63. doi: 10.1016/j.neuropharm.2016.04.042. Epub 2016 Apr 30.

PMID:
27140694
27.

Early postnatal switch in GABAA receptor α-subunits in the reticular thalamic nucleus.

Pangratz-Fuehrer S, Sieghart W, Rudolph U, Parada I, Huguenard JR.

J Neurophysiol. 2016 Mar;115(3):1183-95. doi: 10.1152/jn.00905.2015. Epub 2015 Dec 2.

28.

Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells.

Wittmann P, Grubinger M, Gröger C, Huber H, Sieghart W, Peck-Radosavljevic M, Mikulits W.

BMC Cancer. 2015 Nov 16;15:909. doi: 10.1186/s12885-015-1919-0.

29.

The α1, α2, α3, and γ2 subunits of GABAA receptors show characteristic spatial and temporal expression patterns in rhombencephalic structures during normal human brain development.

Stojanovic T, Capo I, Aronica E, Adle-Biassette H, Höger H, Sieghart W, Kovacs GG, Milenkovic I.

J Comp Neurol. 2016 Jun 15;524(9):1805-24. doi: 10.1002/cne.23923. Epub 2015 Nov 23.

PMID:
26518133
30.

Neurotoxins from snake venoms and α-conotoxin ImI inhibit functionally active ionotropic γ-aminobutyric acid (GABA) receptors.

Kudryavtsev DS, Shelukhina IV, Son LV, Ojomoko LO, Kryukova EV, Lyukmanova EN, Zhmak MN, Dolgikh DA, Ivanov IA, Kasheverov IE, Starkov VG, Ramerstorfer J, Sieghart W, Tsetlin VI, Utkin YN.

J Biol Chem. 2015 Sep 11;290(37):22747-58. doi: 10.1074/jbc.M115.648824. Epub 2015 Jul 28.

31.

Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.

Pinter M, Ulbrich G, Sieghart W, Kölblinger C, Reiberger T, Li S, Ferlitsch A, Müller C, Lammer J, Peck-Radosavljevic M.

Radiology. 2015 Dec;277(3):903-12. doi: 10.1148/radiol.2015142140. Epub 2015 Jul 1.

PMID:
26131911
32.

Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study.

Bucsics T, Mandorfer M, Schwabl P, Bota S, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T.

J Gastroenterol Hepatol. 2015 Nov;30(11):1657-65. doi: 10.1111/jgh.13002.

PMID:
25967931
33.

Transarterial chemoembolization: modalities, indication, and patient selection.

Sieghart W, Hucke F, Peck-Radosavljevic M.

J Hepatol. 2015 May;62(5):1187-95. doi: 10.1016/j.jhep.2015.02.010. Epub 2015 Feb 12. Review.

34.

Allosteric modulation of GABAA receptors via multiple drug-binding sites.

Sieghart W.

Adv Pharmacol. 2015;72:53-96. doi: 10.1016/bs.apha.2014.10.002. Epub 2014 Dec 4. Review.

PMID:
25600367
35.

Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient.

Ferlitsch A, Bota S, Paternostro R, Reiberger T, Mandorfer M, Heinisch B, Salzl P, Schwarzer R, Sieghart W, Peck-Radosavljevic M, Ferlitsch M.

Liver Int. 2015 Sep;35(9):2115-20. doi: 10.1111/liv.12783. Epub 2015 Jan 30.

PMID:
25585656
36.

GABA(A) receptor subtype-selectivity of novel bicuculline derivatives.

Ramerstorfer J, Foppa V, Thiery H, Hermange P, Janody S, Berger ML, Dodd RH, Sieghart W.

Curr Med Chem. 2015;22(6):771-80.

PMID:
25386826
37.

Epidemiological trends of hepatocellular carcinoma in Austria.

Pinter M, Hucke F, Zielonke N, Trauner M, Sieghart W, Peck-Radosavljevic M.

Dig Dis. 2014;32(6):664-9. doi: 10.1159/000367983. Epub 2014 Oct 29.

PMID:
25376282
38.

Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.

Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Summereder C, Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Reiberger T.

PLoS One. 2014 Nov 4;9(11):e110503. doi: 10.1371/journal.pone.0110503. eCollection 2014.

39.

Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma.

Reichl P, Dengler M, van Zijl F, Huber H, Führlinger G, Reichel C, Sieghart W, Peck-Radosavljevic M, Grubinger M, Mikulits W.

Hepatology. 2015 Mar;61(3):930-41. doi: 10.1002/hep.27492. Epub 2015 Jan 28.

40.

EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.

Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic M, Sieghart W, Trauner M, Wang H, Sibilia M.

Nat Cell Biol. 2014 Oct;16(10):972-7. doi: 10.1038/ncb3031. Epub 2014 Aug 31.

41.

How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.

Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M, Sieghart W.

J Hepatol. 2014 Dec;61(6):1287-96. doi: 10.1016/j.jhep.2014.07.002. Epub 2014 Jul 10.

PMID:
25016222
42.

Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma.

Pinter M, Sieghart W, Schmid M, Dauser B, Prager G, Dienes HP, Trauner M, Peck-Radosavljevic M.

United European Gastroenterol J. 2013 Aug;1(4):265-75. doi: 10.1177/2050640613496605.

43.

Reply to the letters to the editor regarding the sequential ART-score.

Hucke F, Sieghart W, Peck-Radosavljevic M.

J Hepatol. 2014 Jul;61(1):177-8. doi: 10.1016/j.jhep.2014.03.015. Epub 2014 Mar 18. No abstract available.

44.

Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.

Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Reiberger T.

Gastroenterology. 2014 Jun;146(7):1680-90.e1. doi: 10.1053/j.gastro.2014.03.005. Epub 2014 Mar 12.

PMID:
24631577
45.

Sh-I-048A, an in vitro non-selective super-agonist at the benzodiazepine site of GABAA receptors: the approximated activation of receptor subtypes may explain behavioral effects.

Obradović ALj, Joksimović S, Poe MM, Ramerstorfer J, Varagic Z, Namjoshi O, Batinić B, Radulović T, Marković B, Roth BL, Sieghart W, Cook JM, Savić MM.

Brain Res. 2014 Mar 20;1554:36-48. doi: 10.1016/j.brainres.2014.01.036. Epub 2014 Jan 25.

46.

Incidence and mortality trends for biliary tract cancers in Austria.

Pinter M, Hucke F, Zielonke N, Waldhör T, Trauner M, Peck-Radosavljevic M, Sieghart W.

Liver Int. 2014 Aug;34(7):1102-8. doi: 10.1111/liv.12325. Epub 2013 Oct 2.

PMID:
24119058
47.

Reply: To PMID 23316013.

Peck-Radosavljevic M, Sieghart W, Hucke F; Vienna HCC Study Group.

Hepatology. 2014 Jun;59(6):2425-6. doi: 10.1002/hep.26765. Epub 2014 Apr 4. No abstract available.

PMID:
24114745
48.

Unexpected Properties of δ-Containing GABAA Receptors in Response to Ligands Interacting with the α+ β- Site.

Mirheydari P, Ramerstorfer J, Varagic Z, Scholze P, Wimmer L, Mihovilovic MM, Sieghart W, Ernst M.

Neurochem Res. 2014 Jun;39(6):1057-1067. doi: 10.1007/s11064-013-1156-3. Epub 2013 Sep 26.

49.

A propofol binding site on mammalian GABAA receptors identified by photolabeling.

Yip GM, Chen ZW, Edge CJ, Smith EH, Dickinson R, Hohenester E, Townsend RR, Fuchs K, Sieghart W, Evers AS, Franks NP.

Nat Chem Biol. 2013 Nov;9(11):715-20. doi: 10.1038/nchembio.1340. Epub 2013 Sep 22.

50.

The parvalbumin-positive interneurons in the mouse dentate gyrus express GABAA receptor subunits α1, β2, and δ along their extrasynaptic cell membrane.

Milenkovic I, Vasiljevic M, Maurer D, Höger H, Klausberger T, Sieghart W.

Neuroscience. 2013 Dec 19;254:80-96. doi: 10.1016/j.neuroscience.2013.09.019. Epub 2013 Sep 17.

PMID:
24055402

Supplemental Content

Loading ...
Support Center